康沣生物-B(06922)公布中期业绩 母公司拥有人应占亏损2381.7万元 同比收窄54.35%

智通财经
Aug 08

智通财经APP讯,康沣生物-B(06922)公布2025年中期业绩,收入5110.6万元,同比增长约1.62倍;毛利3431.2万元,同比增长约1.25倍;母公司拥有人应占亏损2381.7万元,同比收窄54.35%;每股亏损0.1元。

公告称,收入增长主要受于2025年3月获国家药监局批准的恶性狭窄冷冻消融系统及冷冻粘连治疗系统等呼吸介入产品的销量增加所带动。此外,波科国际医疗贸易(上海)有限公司的其他呼吸介入产品的经销销售于报告期间相应增加。亏损收窄是由于公司优化发展策略并实施集团控制开支的有效措施。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10